Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CYBX's Cash to Debt is ranked higher than
89% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. CYBX: No Debt )
CYBX' s 10-Year Cash to Debt Range
Min: 0.64   Max: 25573
Current: No Debt

0.64
25573
Equity to Asset 0.91
CYBX's Equity to Asset is ranked higher than
96% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CYBX: 0.91 )
CYBX' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.94
Current: 0.91

-0.14
0.94
Interest Coverage 4000.60
CYBX's Interest Coverage is ranked higher than
70% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. CYBX: 4000.60 )
CYBX' s 10-Year Interest Coverage Range
Min: 5.59   Max: 9999.99
Current: 4000.6

5.59
9999.99
F-Score: 7
Z-Score: 36.90
M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 31.01
CYBX's Operating margin (%) is ranked higher than
98% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. CYBX: 31.01 )
CYBX' s 10-Year Operating margin (%) Range
Min: -814.29   Max: 30.81
Current: 31.01

-814.29
30.81
Net-margin (%) 20.95
CYBX's Net-margin (%) is ranked higher than
95% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. CYBX: 20.95 )
CYBX' s 10-Year Net-margin (%) Range
Min: -800   Max: 46.76
Current: 20.95

-800
46.76
ROE (%) 22.60
CYBX's ROE (%) is ranked higher than
98% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.61 vs. CYBX: 22.60 )
CYBX' s 10-Year ROE (%) Range
Min: -1275.79   Max: 109.46
Current: 22.6

-1275.79
109.46
ROA (%) 20.60
CYBX's ROA (%) is ranked higher than
99% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. CYBX: 20.60 )
CYBX' s 10-Year ROA (%) Range
Min: -258.97   Max: 50.36
Current: 20.6

-258.97
50.36
ROC (Joel Greenblatt) (%) 89.93
CYBX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 396 Companies
in the Global Medical Devices industry.

( Industry Median: 11.81 vs. CYBX: 89.93 )
CYBX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3466.67   Max: 110.07
Current: 89.93

-3466.67
110.07
Revenue Growth (%) 15.50
CYBX's Revenue Growth (%) is ranked higher than
91% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. CYBX: 15.50 )
CYBX' s 10-Year Revenue Growth (%) Range
Min: 1.5   Max: 180.6
Current: 15.5

1.5
180.6
EBITDA Growth (%) 19.50
CYBX's EBITDA Growth (%) is ranked higher than
92% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: -2.10 vs. CYBX: 19.50 )
CYBX' s 10-Year EBITDA Growth (%) Range
Min: -54.6   Max: 26.3
Current: 19.5

-54.6
26.3
EPS Growth (%) 7.10
CYBX's EPS Growth (%) is ranked higher than
79% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. CYBX: 7.10 )
CYBX' s 10-Year EPS Growth (%) Range
Min: -38.2   Max: 11.2
Current: 7.1

-38.2
11.2
» CYBX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CYBX Guru Trades in Q3 2013

RS Investment Management 612,956 sh (+31.83%)
Paul Tudor Jones 7,000 sh (+12.9%)
Steven Cohen 165,798 sh (+10.09%)
Jim Simons 2,465,894 sh (+6.04%)
John Hussman 509,000 sh (-2.49%)
Joel Greenblatt 7,383 sh (-26.68%)
» More
Q4 2013

CYBX Guru Trades in Q4 2013

RS Investment Management 912,588 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 2,310,094 sh (-6.32%)
John Hussman 355,000 sh (-30.26%)
Joel Greenblatt 5,079 sh (-31.21%)
Steven Cohen 11,957 sh (-92.79%)
» More
Q1 2014

CYBX Guru Trades in Q1 2014

Paul Tudor Jones 6,500 sh (New)
RS Investment Management 1,266,459 sh (+38.78%)
Joel Greenblatt 5,096 sh (+0.33%)
Jim Simons 2,223,194 sh (-3.76%)
John Hussman 266,000 sh (-25.07%)
Steven Cohen 6,700 sh (-43.97%)
» More
Q2 2014

CYBX Guru Trades in Q2 2014

Joel Greenblatt 20,851 sh (+309.16%)
Jim Simons 2,411,201 sh (+8.46%)
Paul Tudor Jones 6,400 sh (-1.54%)
RS Investment Management 1,023,829 sh (-19.16%)
John Hussman 200,000 sh (-24.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Reduce -24.81%0.32%$57.14 - $65.99 $ 54.39-11%200000
Joel Greenblatt 2014-06-30 Add 309.16%0.01%$57.14 - $65.99 $ 54.39-11%20851
John Hussman 2014-03-31 Reduce -25.07%0.43%$62 - $72.98 $ 54.39-19%266000
John Hussman 2013-12-31 Reduce -30.26%0.42%$50.84 - $71.5 $ 54.39-10%355000
Joel Greenblatt 2013-12-31 Reduce -31.21%$50.84 - $71.5 $ 54.39-10%5079
Joel Greenblatt 2013-09-30 Reduce -26.68%0.01%$50.51 - $56 $ 54.394%7383
John Hussman 2013-06-30 Reduce -41.87%0.63%$42.97 - $52.54 $ 54.3915%522000
Joel Greenblatt 2013-06-30 Reduce -23.68%0.01%$42.97 - $52.54 $ 54.3915%10070
Joel Greenblatt 2013-03-31 Add 113.1%0.02%$42.73 - $55.42 $ 54.3914%13195
Joel Greenblatt 2012-12-31 New Buy0.02%$44.5 - $53.23 $ 54.398%6192
Joel Greenblatt 2012-03-31 Sold Out 0.05%$32.18 - $39.01 $ 54.3966%0
Joel Greenblatt 2011-12-31 Reduce -24.38%0.02%$26.93 - $34.2 $ 54.3983%12604
Carl Icahn 2011-09-30 Sold Out 0.98%$23.7 - $30 $ 54.3999%0
Joel Greenblatt 2011-09-30 Add 27.85%0.02%$23.7 - $30 $ 54.3999%16667
Joel Greenblatt 2011-06-30 Reduce -23.28%0.04%$24.94 - $35.59 $ 54.3974%13036
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
CYBX's P/E(ttm) is ranked higher than
85% of the 419 Companies
in the Global Medical Devices industry.

( Industry Median: 64.90 vs. CYBX: 24.80 )
CYBX' s 10-Year P/E(ttm) Range
Min: 6.15   Max: 219.29
Current: 24.8

6.15
219.29
P/B 5.49
CYBX's P/B is ranked higher than
58% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. CYBX: 5.49 )
CYBX' s 10-Year P/B Range
Min: 3.92   Max: 180.33
Current: 5.49

3.92
180.33
P/S 5.19
CYBX's P/S is ranked higher than
61% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. CYBX: 5.19 )
CYBX' s 10-Year P/S Range
Min: 2.16   Max: 10.82
Current: 5.19

2.16
10.82
PFCF 30.39
CYBX's PFCF is ranked higher than
87% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 30.39 )
CYBX' s 10-Year PFCF Range
Min: 10   Max: 1235.33
Current: 30.39

10
1235.33
EV-to-EBIT 14.95
CYBX's EV-to-EBIT is ranked higher than
91% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 45.27 vs. CYBX: 14.95 )
CYBX' s 10-Year EV-to-EBIT Range
Min: 12.3   Max: 309.6
Current: 14.95

12.3
309.6
PEG 1.13
CYBX's PEG is ranked higher than
98% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 1.13 )
CYBX' s 10-Year PEG Range
Min: 0.74   Max: 1.85
Current: 1.13

0.74
1.85
Shiller P/E 30.07
CYBX's Shiller P/E is ranked higher than
88% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 30.07 )
CYBX' s 10-Year Shiller P/E Range
Min: 29.81   Max: 214.29
Current: 30.07

29.81
214.29
Current Ratio 8.91
CYBX's Current Ratio is ranked higher than
95% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. CYBX: 8.91 )
CYBX' s 10-Year Current Ratio Range
Min: 0.81   Max: 15.71
Current: 8.91

0.81
15.71
Quick Ratio 8.13
CYBX's Quick Ratio is ranked higher than
96% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. CYBX: 8.13 )
CYBX' s 10-Year Quick Ratio Range
Min: 0.69   Max: 15.35
Current: 8.13

0.69
15.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.53
CYBX's Price/Net Cash is ranked higher than
91% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 13.53 )
CYBX' s 10-Year Price/Net Cash Range
Min: 5.63   Max: 136.76
Current: 13.53

5.63
136.76
Price/Net Current Asset Value 9.49
CYBX's Price/Net Current Asset Value is ranked higher than
89% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 9.49 )
CYBX' s 10-Year Price/Net Current Asset Value Range
Min: 5.26   Max: 675
Current: 9.49

5.26
675
Price/Tangible Book 5.73
CYBX's Price/Tangible Book is ranked higher than
69% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. CYBX: 5.73 )
CYBX' s 10-Year Price/Tangible Book Range
Min: 2.02   Max: 178.58
Current: 5.73

2.02
178.58
Price/DCF (Projected) 1.67
CYBX's Price/DCF (Projected) is ranked higher than
89% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 123.59 vs. CYBX: 1.67 )
CYBX' s 10-Year Price/DCF (Projected) Range
Min: 1.73   Max: 93.7
Current: 1.67

1.73
93.7
Price/Median PS Value 1.10
CYBX's Price/Median PS Value is ranked higher than
75% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 1.17 vs. CYBX: 1.10 )
CYBX' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 20.16
Current: 1.1

0.53
20.16
Price/Peter Lynch Fair Value 1.12
CYBX's Price/Peter Lynch Fair Value is ranked higher than
98% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 1.12 )
CYBX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.05   Max: 2.79
Current: 1.12

1.05
2.79
Price/Graham Number 2.49
CYBX's Price/Graham Number is ranked higher than
82% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 7.56 vs. CYBX: 2.49 )
CYBX' s 10-Year Price/Graham Number Range
Min: 1.05   Max: 10.89
Current: 2.49

1.05
10.89
Earnings Yield (Greenblatt) 6.70
CYBX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. CYBX: 6.70 )
CYBX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 8.1
Current: 6.7

0.3
8.1
Forward Rate of Return (Yacktman) 24.42
CYBX's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.32 vs. CYBX: 24.42 )
CYBX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: 38.2
Current: 24.42

-8.1
38.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:JC8.Germany
Cyberonics, Inc. was incorporated in the state of Delaware in 1987. The Company is a medical device company. It is engaged in the design, development, sales and marketing of implantable medical devices that provide a unique therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression. The Company's proprietary VNS Therapy System includes: An implantable pulse generator to provide stimulation to the vagus nerve; A lead that connects the generator to the vagus nerve; Equipment to assist with the implant procedure; Equipment to assist the treating physician with setting the stimulation parameters for each patient; Instruction manuals; and Magnets to temporarily suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The battery contained in the generator has a finite life, which varies according to the model as well as the stimulation parameters for each patient. At or near the end of the useful life of a battery, a patient may, with the advice of a physician, choose to implant a new generator, which may be done with or without replacing the original lead. The Company sells the VNS Therapy System to hospitals and ambulatory surgery centers ('ASCs') on payment terms that are generally 30 days from the shipment date. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
» More Articles for CYBX

Headlines

Articles On GuruFocus.com
comment on CYBX Feb 24 2013 
comment on CYBX Jan 26 2013 
Cyberonics Inc. (CYBX) President & CEO Daniel Jeffrey Moore sells 44,700 Shares Jan 13 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 10,000 Shares Jan 12 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 5,000 Shares Dec 08 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 22 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Aug 26 2010 
Cyberonics Inc. Reports Operating Results (10-K) Jun 17 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Feb 18 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 19 2009 

More From Other Websites
Insider Trading Alert - AMTD, CYBX And RSG Traded By Insiders Sep 15 2014
Cyberonics Down 3.6% despite Favorable ANTHEM-HF Results Sep 05 2014
ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With... Sep 02 2014
Cyberonics device improves heart function after Boston flop Sep 01 2014
CYBERONICS INC Financials Aug 28 2014
Cyberonics Slips to Sell on U.S. Woes, Estimate Revisions Aug 25 2014
Cyberonics downgraded by Canaccord Genuity Aug 22 2014
Cyberonics Misses on Q1 Earnings & Revenues, Reaffirms View Aug 22 2014
Cyberonics Slumps: CYBX Falls 6.1% in Session Aug 22 2014
Cyberonics to Participate in Upcoming Investor Conferences Aug 21 2014
Q1 2015 Cyberonics Earnings Release - Before Market Open Aug 21 2014
CYBERONICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 21 2014
Cyberonics Reports Fiscal 2015 First Quarter Results Aug 21 2014
Cyberonics To Report Fiscal Year 2015 First Quarter Results And Host Webcast And Conference Call On... Aug 07 2014
Why is Cyberonics Downgraded to Sell? Jul 09 2014
Cyberonics Poised on Favorable Market Trend Jul 03 2014
Insider Trading Alert - RSG, ENH And CYBX Traded By Insiders Jun 25 2014
UPDATE: Sterne Agee Initiates Coverage On Cyberonics Jun 24 2014
CYBERONICS INC Files SEC form 10-K, Annual Report Jun 16 2014
Cyberonics Posts In-Line Q4 Earnings, Misses on Revs Jun 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK